SlideShare a Scribd company logo
1 of 23
GeoVax Labs, Inc. October 14, 2011 Greater Rome Chamber of Commerce 2011 Technology Symposium  O11_IRG
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Disclaimer
SOURCE:  2009 Report on the Global AIDS Epidemic, UNAIDS/WHO (December 2009) Total Living with HIV: 33.4M  Total Clade B: 3.5M New Infections: 2.7M   New Clade B:185,400 HIV/AIDS – A Continuing Global Challenge O11_IRG /  North America 1.4 M 55,000 NEW Caribbean 240,000 20,000 NEW Latin America Clade B 900,000 76,500 NEW Western/Central Europe 850,000 30,000 NEW Middle East / North Africa 310,000 35,000 NEW Sub-Saharan Africa 22.4M 1.9 M NEW Eastern Europe/ Central Asia 1.5 M 110,000 NEW South/Southeast Asia 3.8 M 280,000 NEW Oceania 59,000 3,900 NEW East Asia 850,000 75,000 NEW Latin America Other 900,000 93,500 NEW B B B B C C C
SOURCE:  CDC Fact Sheet – Estimates of New HIV Infections in the United States (August 2008) Current Rate of New Infection:55,000-58,000 per year * Estimated Cost for Each U.S. Infection = $500,000 (Aggregate, $27.5 billion/year) * AIDS 2010 Annual Meeting (Atlanta GA) Estimates for New HIV Infections in US O11_IRG /  0 1979 1983 1987 1989 1993 1997 2001 2005 20,000 40,000 60,000 80,000 100,000 120,000 140,000
Impact of a Preventative AIDS Vaccine A 50% effective vaccine given to just 30% of the population could cut the 33 million projected number of new HIV infections in the developing world by more than half over 15 years. SOURCE:  AIDS Vaccine Blueprint 2006, IAVI Report NOTE:  Polio Vaccine is 60-70% effective / Flu Vaccine 70-90% effective O11_XTRA /  NO VACCINE Vaccine Introduction 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 2010  2015  2020  2025  2030 30% Efficacy 20% Coverage 50% Efficacy 30% Coverage 70% Efficacy 40% Coverage Total New Infections Averted by an AIDS Vaccine between 2015 - 2030 5.5 Million 17 Million 28 Million
Total Annual Global Revenue* Projections for 1 st  Generation AIDS Vaccines * Only Preventative Vaccine Revenue Reported; Therapeutic Market Estimated at $3.6B US/$3.6B ROW SOURCE:  IAVI, October 2007 HIV/AIDS Preventative Vaccine Market O11_IRG /  SCENARIO HIGH OPTIMISTIC BASELINE BASELINE LOW Peak Global Revenue $5.5B $4.8B $4.5B $2.5B Avg. Annual Sales Revenue (over years 0-30) $4.3B $3.2B $2.6B $1.4B Cumulative Sales Revenue over 30 year period $134.4B $98.4B $81.7B $43.8B 6 5 4 3 2 1 0 0  5  10  15  20  25  30 Years since FDA/EMEA regulatory approval
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GeoVax Company Overview O11_IRG /
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GeoVax Corporate Management O11_IRG /
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GeoVax Board of Directors O11_IRG /
COMPLETE PLANNED Product Portfolio  O11_IRG /  NOT REQUIRED
Preventative Vaccine
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GeoVax Preventative AIDS Vaccine O11_IRG /
Phase 1 Human Trial – Government Supported Published by  The Journal of Infectious Diseases Challenge Dose 30-300 Times Higher Than Typical Human Dose DNA Vaccine with GM-CSF Adjuvant (Primate Data) O11_IRG /  0 80 100 60 40 20 Number of Challenges 0 2 4 6 8 12 10 Percent Uninfected 70% Prevention of Infection 5 / 7 No Evidence of Infection – To Date >12 Months 100% Infection Controls (0 / 15 Protected)
Therapeutic Vaccine
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GeoVax Therapeutic Vaccine O11_IRG /
Unpublished Data: Dr. Rama Amara & Dr. Harriet Robinson 100x 1000x VACCINATION Pre-Clinical Therapeutic Trial Results O11_IRG /  RJu9 Rlr9   0  12  50  58  66  72  112 10 7 10 5 10 3 Weeks Following Infection Infection Drug Treatment Started DNA DNA MVA Drug Treatment Interruption
GeoVax Vaccine Technology
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Strong Proprietary Technology Position O11_XTRA /
Rate of Vaccine Responses *  Responding T cells, intracellular cytokine staining **  Anti-Env binding AB, ELISA ***  After 6 intrarectal challenges with a dose 40-400 times higher than typical human dose NOTE:  Polio Vaccine is 60-70% effective / Flu Vaccine 70-90% effective O11_XTRA /
Current Status: Therapeutic AIDS Vaccines O11_XTRA /  Vaccine Sponsor Antibody (Ab to Env) T Cell Comments Bavarian Nordic MVA/BN Multiantigen NO YES Phase 1 Completed CD4 & CD8 T cells Bionor Immuno Vacc-4x Peptides NO YES Phase 2 Completed CD4 T cells but limited Response Rates Inovio PENNVAX™-B (pDNA) Unknown YES Phase 1 Active U Penn vaccine, CD4 & CD8 T cells Profectus BioSciences Multiantigen DNA + rVSV Unknown Unknown 2010 Start Planned ACTG Study GSK gp120+nef/tat fusion proteins & adjuvant YES YES Phase 1 Completed Low level neutralizing Ab, CD4 T cells Argos Therapeutics AGS-004 (RNA transfect DC) NO YES Phase 2b Active Personalized medicine approach GEOVAX DNA / MVA YES * YES * Phase 1 Enrolling * Data from GV  Phase 1 trial in HIV Uninfected
Current Status: Preventative AIDS Vaccines Out of more than 80 vaccines entering HVTN Phase 1 testing, GeoVax Vaccines represent 2 of 6 to progress to Phase 2 O11_XTRA /  Vaccine Sponsor Antibody (Ab to Env) T Cell Comments VaxGen gp 120 YES NO FAILED gp120, atypical Env Merck Ad5 NO YES FAILED Ad5 seropositive participants at higher risk NIH / VRC DNA Ad5 YES YES ENROLLING Limited to Ad5 seronegative, circumcised Not intended as commercial product Aventis ALVAC / gp120 YES LOW TRIAL COMPLETE Prevention of infection in 31% of Participants GEOVAX DNA / MVA YES YES PHASE 2a Enrollment Complete GEOVAX MVA / MVA YES YES PHASE 2a Addendum Enrollment Started December 2010
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],GeoVax -- Summary O11_IRG /
GeoVax Labs, Inc. Thank You!!

More Related Content

What's hot

Know your COVID-19 Vaccine (Philippines)
Know your COVID-19 Vaccine (Philippines)Know your COVID-19 Vaccine (Philippines)
Know your COVID-19 Vaccine (Philippines)AxcelPerez1
 
Moderna mRNA Vaccines: from Concept to Clinic
Moderna mRNA Vaccines: from Concept to ClinicModerna mRNA Vaccines: from Concept to Clinic
Moderna mRNA Vaccines: from Concept to ClinicModernaTherapeutics1
 
Pfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine AnnouncementPfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine AnnouncementRachelMackelprang
 
An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...
An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...
An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...EuFMD
 
S3 orlandini presentation about prognosis models
S3 orlandini presentation about prognosis modelsS3 orlandini presentation about prognosis models
S3 orlandini presentation about prognosis modelsĐomla Čučak
 
COVID-19 Vaccines Update (End Q1 2021)
COVID-19 Vaccines Update (End Q1 2021)COVID-19 Vaccines Update (End Q1 2021)
COVID-19 Vaccines Update (End Q1 2021)Kumaraguru Veerasamy
 
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例hprc_tmu
 
All about Covid-19 Vaccine Development
All about Covid-19 Vaccine DevelopmentAll about Covid-19 Vaccine Development
All about Covid-19 Vaccine DevelopmentShivam Parmar
 
Disease monitoring in wheat through remotely sensed data
Disease monitoring in wheat through remotely sensed dataDisease monitoring in wheat through remotely sensed data
Disease monitoring in wheat through remotely sensed dataCIMMYT
 
COVID-19 Therapeutics Update (End Q1 2021)
COVID-19 Therapeutics Update (End Q1 2021)COVID-19 Therapeutics Update (End Q1 2021)
COVID-19 Therapeutics Update (End Q1 2021)Kumaraguru Veerasamy
 
التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...
التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...
التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...Mohamed Mostafa
 
Coronavirus Pandemic Part III (A): Diagnostic Technologies
Coronavirus Pandemic Part III (A): Diagnostic TechnologiesCoronavirus Pandemic Part III (A): Diagnostic Technologies
Coronavirus Pandemic Part III (A): Diagnostic TechnologiesKumaraguru Veerasamy
 
Clinical Trials & Drug Approval Process
Clinical Trials & Drug Approval ProcessClinical Trials & Drug Approval Process
Clinical Trials & Drug Approval ProcessKumaraguru Veerasamy
 
Covid-19 Vaccine Market Rally
Covid-19 Vaccine Market RallyCovid-19 Vaccine Market Rally
Covid-19 Vaccine Market RallyInvestingTips
 
Covid 19 Vaccination SCM Analysis
Covid 19 Vaccination SCM AnalysisCovid 19 Vaccination SCM Analysis
Covid 19 Vaccination SCM AnalysisTejNarayanShaw2
 
Global germplasm collections: sure benefits without seedborne diseases
Global germplasm collections: sure benefits without seedborne diseasesGlobal germplasm collections: sure benefits without seedborne diseases
Global germplasm collections: sure benefits without seedborne diseasesCIAT
 
BioWorldToday03082016
BioWorldToday03082016BioWorldToday03082016
BioWorldToday03082016steve666
 
SARS-CoV-2 variants of concern and variants under investigation in England
SARS-CoV-2 variants of concern and variants under investigation in EnglandSARS-CoV-2 variants of concern and variants under investigation in England
SARS-CoV-2 variants of concern and variants under investigation in EnglandSociété Tripalio
 

What's hot (20)

Know your COVID-19 Vaccine (Philippines)
Know your COVID-19 Vaccine (Philippines)Know your COVID-19 Vaccine (Philippines)
Know your COVID-19 Vaccine (Philippines)
 
Moderna mRNA Vaccines: from Concept to Clinic
Moderna mRNA Vaccines: from Concept to ClinicModerna mRNA Vaccines: from Concept to Clinic
Moderna mRNA Vaccines: from Concept to Clinic
 
Pfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine AnnouncementPfizer's SARS-CoV-2 Vaccine Announcement
Pfizer's SARS-CoV-2 Vaccine Announcement
 
An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...
An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...
An overview of reverse genetic approaches to enhanced FMD vaccines in Africa ...
 
S3 orlandini presentation about prognosis models
S3 orlandini presentation about prognosis modelsS3 orlandini presentation about prognosis models
S3 orlandini presentation about prognosis models
 
COVID-19 Vaccines Update (End Q1 2021)
COVID-19 Vaccines Update (End Q1 2021)COVID-19 Vaccines Update (End Q1 2021)
COVID-19 Vaccines Update (End Q1 2021)
 
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例疫苗研發之產學研合作經驗分享以冠狀病毒奈米疫苗為例
疫苗研發之產學研合作經驗分享 以冠狀病毒奈米疫苗為例
 
Uk variant SARS CoV 2
Uk variant SARS CoV 2Uk variant SARS CoV 2
Uk variant SARS CoV 2
 
COVID-19 Therapies and Vaccines
COVID-19 Therapies and VaccinesCOVID-19 Therapies and Vaccines
COVID-19 Therapies and Vaccines
 
All about Covid-19 Vaccine Development
All about Covid-19 Vaccine DevelopmentAll about Covid-19 Vaccine Development
All about Covid-19 Vaccine Development
 
Disease monitoring in wheat through remotely sensed data
Disease monitoring in wheat through remotely sensed dataDisease monitoring in wheat through remotely sensed data
Disease monitoring in wheat through remotely sensed data
 
COVID-19 Therapeutics Update (End Q1 2021)
COVID-19 Therapeutics Update (End Q1 2021)COVID-19 Therapeutics Update (End Q1 2021)
COVID-19 Therapeutics Update (End Q1 2021)
 
التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...
التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...
التقدم في تكنولوجيا المعلومات للكشف عن أمراض النباتات Advances in Informatio...
 
Coronavirus Pandemic Part III (A): Diagnostic Technologies
Coronavirus Pandemic Part III (A): Diagnostic TechnologiesCoronavirus Pandemic Part III (A): Diagnostic Technologies
Coronavirus Pandemic Part III (A): Diagnostic Technologies
 
Clinical Trials & Drug Approval Process
Clinical Trials & Drug Approval ProcessClinical Trials & Drug Approval Process
Clinical Trials & Drug Approval Process
 
Covid-19 Vaccine Market Rally
Covid-19 Vaccine Market RallyCovid-19 Vaccine Market Rally
Covid-19 Vaccine Market Rally
 
Covid 19 Vaccination SCM Analysis
Covid 19 Vaccination SCM AnalysisCovid 19 Vaccination SCM Analysis
Covid 19 Vaccination SCM Analysis
 
Global germplasm collections: sure benefits without seedborne diseases
Global germplasm collections: sure benefits without seedborne diseasesGlobal germplasm collections: sure benefits without seedborne diseases
Global germplasm collections: sure benefits without seedborne diseases
 
BioWorldToday03082016
BioWorldToday03082016BioWorldToday03082016
BioWorldToday03082016
 
SARS-CoV-2 variants of concern and variants under investigation in England
SARS-CoV-2 variants of concern and variants under investigation in EnglandSARS-CoV-2 variants of concern and variants under investigation in England
SARS-CoV-2 variants of concern and variants under investigation in England
 

Viewers also liked

10. green carbon, inc fred taylor & phil wilson
10. green carbon, inc   fred taylor & phil wilson10. green carbon, inc   fred taylor & phil wilson
10. green carbon, inc fred taylor & phil wilsonGreaterRomeChamber
 
4. tri max electric vehicle - jim davis
4. tri max electric vehicle - jim davis4. tri max electric vehicle - jim davis
4. tri max electric vehicle - jim davisGreaterRomeChamber
 
Textual analysis - Contents pages.
Textual analysis - Contents pages.Textual analysis - Contents pages.
Textual analysis - Contents pages.Nicoline Granheim
 
Textual analysis - Double page spread
Textual analysis - Double page spreadTextual analysis - Double page spread
Textual analysis - Double page spreadNicoline Granheim
 
5. healthcare in motion panel discussion
5. healthcare in motion panel discussion5. healthcare in motion panel discussion
5. healthcare in motion panel discussionGreaterRomeChamber
 

Viewers also liked (8)

10. green carbon, inc fred taylor & phil wilson
10. green carbon, inc   fred taylor & phil wilson10. green carbon, inc   fred taylor & phil wilson
10. green carbon, inc fred taylor & phil wilson
 
4. tri max electric vehicle - jim davis
4. tri max electric vehicle - jim davis4. tri max electric vehicle - jim davis
4. tri max electric vehicle - jim davis
 
Textual analysis - Contents pages.
Textual analysis - Contents pages.Textual analysis - Contents pages.
Textual analysis - Contents pages.
 
2. trip lingo ross rankin
2. trip lingo   ross rankin2. trip lingo   ross rankin
2. trip lingo ross rankin
 
Textual analysis - Double page spread
Textual analysis - Double page spreadTextual analysis - Double page spread
Textual analysis - Double page spread
 
Frames
FramesFrames
Frames
 
5. healthcare in motion panel discussion
5. healthcare in motion panel discussion5. healthcare in motion panel discussion
5. healthcare in motion panel discussion
 
Irtisanomisia, lomautuksia ja yt-neuvotteluja 2016
Irtisanomisia, lomautuksia ja yt-neuvotteluja 2016Irtisanomisia, lomautuksia ja yt-neuvotteluja 2016
Irtisanomisia, lomautuksia ja yt-neuvotteluja 2016
 

Similar to GeoVax Presents at 2011 Technology Symposium

Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...hivlifeinfo
 
1810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v71810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v7targovax2017
 
Clinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleClinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleHivlife Info
 
Clinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleClinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,Seattlehivlifeinfo
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5targovax2017
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2Galenabio
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2Galenabio
 
Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next levelTaking Immunotherapy to the Next level
Taking Immunotherapy to the Next levelCompany Spotlight
 
Galena presentation 8 apr 16
Galena presentation   8 apr 16 Galena presentation   8 apr 16
Galena presentation 8 apr 16 Galenabio
 
Galena presentation 11 may 16
Galena presentation   11 may 16 Galena presentation   11 may 16
Galena presentation 11 may 16 Galenabio
 
Galena presentation 14 mar 16
Galena presentation   14 mar 16 Galena presentation   14 mar 16
Galena presentation 14 mar 16 Galenabio
 
Galena presentation 3 june 16
Galena presentation   3 june 16Galena presentation   3 june 16
Galena presentation 3 june 16Galenabio
 
Inovio - Revolutionizing the Fight Against Cancers and Infectious Diseases
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesInovio - Revolutionizing the Fight Against Cancers and Infectious Diseases
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesCompany Spotlight
 
Executive Summary 2009 Project Continuation With Pics
Executive Summary 2009 Project Continuation  With PicsExecutive Summary 2009 Project Continuation  With Pics
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
 
Executive Summary 2009 Project Continuation With Pics
Executive Summary 2009 Project Continuation  With PicsExecutive Summary 2009 Project Continuation  With Pics
Executive Summary 2009 Project Continuation With Picsguestcbe9f3
 
Galena presentation 8 feb 16
Galena presentation  8 feb 16Galena presentation  8 feb 16
Galena presentation 8 feb 16Galenabio
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16 Galenabio
 
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
Современное лечение ВИЧ.Объединенные данные с конференции  IAS 2019 / Contemp...Современное лечение ВИЧ.Объединенные данные с конференции  IAS 2019 / Contemp...
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...hivlifeinfo
 

Similar to GeoVax Presents at 2011 Technology Symposium (20)

Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
Choosing Among Current Antiretroviral Regimens.The Relevance of Drug–Drug Int...
 
1810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v71810 3 q-2018-presentation-v7
1810 3 q-2018-presentation-v7
 
Clinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleClinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,Seattle
 
Clinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,SeattleClinical Impact of Data From the CROI 2015,Seattle
Clinical Impact of Data From the CROI 2015,Seattle
 
180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5180823 2 q 2018 presentation v5
180823 2 q 2018 presentation v5
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2
 
Q2, 2016 earnings slides final2
Q2, 2016 earnings slides   final2Q2, 2016 earnings slides   final2
Q2, 2016 earnings slides final2
 
Taking Immunotherapy to the Next level
Taking Immunotherapy to the Next levelTaking Immunotherapy to the Next level
Taking Immunotherapy to the Next level
 
Galena presentation 8 apr 16
Galena presentation   8 apr 16 Galena presentation   8 apr 16
Galena presentation 8 apr 16
 
Galena presentation 11 may 16
Galena presentation   11 may 16 Galena presentation   11 may 16
Galena presentation 11 may 16
 
Galena presentation 14 mar 16
Galena presentation   14 mar 16 Galena presentation   14 mar 16
Galena presentation 14 mar 16
 
Galena presentation 3 june 16
Galena presentation   3 june 16Galena presentation   3 june 16
Galena presentation 3 june 16
 
Inovio - Revolutionizing the Fight Against Cancers and Infectious Diseases
Inovio - Revolutionizing the Fight Against Cancers and Infectious DiseasesInovio - Revolutionizing the Fight Against Cancers and Infectious Diseases
Inovio - Revolutionizing the Fight Against Cancers and Infectious Diseases
 
Executive Summary 2009 Project Continuation With Pics
Executive Summary 2009 Project Continuation  With PicsExecutive Summary 2009 Project Continuation  With Pics
Executive Summary 2009 Project Continuation With Pics
 
Executive Summary 2009 Project Continuation With Pics
Executive Summary 2009 Project Continuation  With PicsExecutive Summary 2009 Project Continuation  With Pics
Executive Summary 2009 Project Continuation With Pics
 
Galena presentation 8 feb 16
Galena presentation  8 feb 16Galena presentation  8 feb 16
Galena presentation 8 feb 16
 
Vaccine101, Dynport Vaccine Company LLC
Vaccine101, Dynport Vaccine Company LLCVaccine101, Dynport Vaccine Company LLC
Vaccine101, Dynport Vaccine Company LLC
 
Q3, 2016 earnings slides 9 nov 16
Q3, 2016 earnings slides   9 nov 16 Q3, 2016 earnings slides   9 nov 16
Q3, 2016 earnings slides 9 nov 16
 
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
Современное лечение ВИЧ.Объединенные данные с конференции  IAS 2019 / Contemp...Современное лечение ВИЧ.Объединенные данные с конференции  IAS 2019 / Contemp...
Современное лечение ВИЧ.Объединенные данные с конференции IAS 2019 / Contemp...
 
Company Profile
Company ProfileCompany Profile
Company Profile
 

More from GreaterRomeChamber

9. berry genetics enterprise anthony bonazza
9. berry genetics enterprise   anthony bonazza9. berry genetics enterprise   anthony bonazza
9. berry genetics enterprise anthony bonazzaGreaterRomeChamber
 
8. medical device manufacturing breakout session
8. medical device manufacturing breakout session8. medical device manufacturing breakout session
8. medical device manufacturing breakout sessionGreaterRomeChamber
 
7. digital technology breakout session
7. digital technology breakout session7. digital technology breakout session
7. digital technology breakout sessionGreaterRomeChamber
 
3. 7hills makerspace greg richardson
3. 7hills makerspace   greg richardson3. 7hills makerspace   greg richardson
3. 7hills makerspace greg richardsonGreaterRomeChamber
 
1. keynote dominic mack morehouse school of medicine
1. keynote dominic mack   morehouse school of medicine1. keynote dominic mack   morehouse school of medicine
1. keynote dominic mack morehouse school of medicineGreaterRomeChamber
 
13. closing remarks david dodd - the past is prologue
13. closing remarks   david dodd - the past is prologue13. closing remarks   david dodd - the past is prologue
13. closing remarks david dodd - the past is prologueGreaterRomeChamber
 
11. now what getting started - chris carey & jerry sims
11. now what   getting started - chris carey & jerry sims11. now what   getting started - chris carey & jerry sims
11. now what getting started - chris carey & jerry simsGreaterRomeChamber
 

More from GreaterRomeChamber (7)

9. berry genetics enterprise anthony bonazza
9. berry genetics enterprise   anthony bonazza9. berry genetics enterprise   anthony bonazza
9. berry genetics enterprise anthony bonazza
 
8. medical device manufacturing breakout session
8. medical device manufacturing breakout session8. medical device manufacturing breakout session
8. medical device manufacturing breakout session
 
7. digital technology breakout session
7. digital technology breakout session7. digital technology breakout session
7. digital technology breakout session
 
3. 7hills makerspace greg richardson
3. 7hills makerspace   greg richardson3. 7hills makerspace   greg richardson
3. 7hills makerspace greg richardson
 
1. keynote dominic mack morehouse school of medicine
1. keynote dominic mack   morehouse school of medicine1. keynote dominic mack   morehouse school of medicine
1. keynote dominic mack morehouse school of medicine
 
13. closing remarks david dodd - the past is prologue
13. closing remarks   david dodd - the past is prologue13. closing remarks   david dodd - the past is prologue
13. closing remarks david dodd - the past is prologue
 
11. now what getting started - chris carey & jerry sims
11. now what   getting started - chris carey & jerry sims11. now what   getting started - chris carey & jerry sims
11. now what getting started - chris carey & jerry sims
 

Recently uploaded

SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Classmanuelazg2001
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurNavdeep Kaur
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...MehranMouzam
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxSasikiranMarri
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfMyThaoAiDoan
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledgeassessoriafabianodea
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxraviapr7
 
SGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdf
SGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdfSGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdf
SGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdfHongBiThi1
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptxBibekananda shah
 
Chronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptx
Chronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptxChronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptx
Chronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptxSasikiranMarri
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medicationMohamadAlhes
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityHarshChauhan475104
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
 

Recently uploaded (20)

SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
Nutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience ClassNutrition of OCD for my Nutritional Neuroscience Class
Nutrition of OCD for my Nutritional Neuroscience Class
 
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaurMETHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
METHODS OF ACQUIRING KNOWLEDGE IN NURSING.pptx by navdeep kaur
 
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
Wessex Health Partners Wessex Integrated Care, Population Health, Research & ...
 
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
Study on the Impact of FOCUS-PDCA Management Model on the Disinfection Qualit...
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Informed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptxInformed Consent Empowering Healthcare Decision-Making.pptx
Informed Consent Empowering Healthcare Decision-Making.pptx
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdfCCSC6142 Week 3 Research ethics - Long Hoang.pdf
CCSC6142 Week 3 Research ethics - Long Hoang.pdf
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-KnowledgeGiftedness: Understanding Everyday Neurobiology for Self-Knowledge
Giftedness: Understanding Everyday Neurobiology for Self-Knowledge
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
Musculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptxMusculoskeletal disorders: Osteoarthritis,.pptx
Musculoskeletal disorders: Osteoarthritis,.pptx
 
SGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdf
SGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdfSGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdf
SGK NĂNG LƯỢNG SINH HỌC MỚI 2019 RẤT HAY NHÉ.pdf
 
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
COVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptxCOVID-19  (NOVEL CORONA  VIRUS DISEASE PANDEMIC ).pptx
COVID-19 (NOVEL CORONA VIRUS DISEASE PANDEMIC ).pptx
 
Chronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptx
Chronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptxChronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptx
Chronic-Fatigue-Syndrome-CFS-Understanding-a-Complex-Disorder.pptx
 
Valproic Acid. (VPA). Antiseizure medication
Valproic Acid.  (VPA). Antiseizure medicationValproic Acid.  (VPA). Antiseizure medication
Valproic Acid. (VPA). Antiseizure medication
 
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand UniversityCEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
CEHPALOSPORINS.pptx By Harshvardhan Dev Bhoomi Uttarakhand University
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisVarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic Analysis
 

GeoVax Presents at 2011 Technology Symposium

  • 1. GeoVax Labs, Inc. October 14, 2011 Greater Rome Chamber of Commerce 2011 Technology Symposium O11_IRG
  • 2.
  • 3. SOURCE: 2009 Report on the Global AIDS Epidemic, UNAIDS/WHO (December 2009) Total Living with HIV: 33.4M Total Clade B: 3.5M New Infections: 2.7M New Clade B:185,400 HIV/AIDS – A Continuing Global Challenge O11_IRG / North America 1.4 M 55,000 NEW Caribbean 240,000 20,000 NEW Latin America Clade B 900,000 76,500 NEW Western/Central Europe 850,000 30,000 NEW Middle East / North Africa 310,000 35,000 NEW Sub-Saharan Africa 22.4M 1.9 M NEW Eastern Europe/ Central Asia 1.5 M 110,000 NEW South/Southeast Asia 3.8 M 280,000 NEW Oceania 59,000 3,900 NEW East Asia 850,000 75,000 NEW Latin America Other 900,000 93,500 NEW B B B B C C C
  • 4. SOURCE: CDC Fact Sheet – Estimates of New HIV Infections in the United States (August 2008) Current Rate of New Infection:55,000-58,000 per year * Estimated Cost for Each U.S. Infection = $500,000 (Aggregate, $27.5 billion/year) * AIDS 2010 Annual Meeting (Atlanta GA) Estimates for New HIV Infections in US O11_IRG / 0 1979 1983 1987 1989 1993 1997 2001 2005 20,000 40,000 60,000 80,000 100,000 120,000 140,000
  • 5. Impact of a Preventative AIDS Vaccine A 50% effective vaccine given to just 30% of the population could cut the 33 million projected number of new HIV infections in the developing world by more than half over 15 years. SOURCE: AIDS Vaccine Blueprint 2006, IAVI Report NOTE: Polio Vaccine is 60-70% effective / Flu Vaccine 70-90% effective O11_XTRA / NO VACCINE Vaccine Introduction 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 2010 2015 2020 2025 2030 30% Efficacy 20% Coverage 50% Efficacy 30% Coverage 70% Efficacy 40% Coverage Total New Infections Averted by an AIDS Vaccine between 2015 - 2030 5.5 Million 17 Million 28 Million
  • 6. Total Annual Global Revenue* Projections for 1 st Generation AIDS Vaccines * Only Preventative Vaccine Revenue Reported; Therapeutic Market Estimated at $3.6B US/$3.6B ROW SOURCE: IAVI, October 2007 HIV/AIDS Preventative Vaccine Market O11_IRG / SCENARIO HIGH OPTIMISTIC BASELINE BASELINE LOW Peak Global Revenue $5.5B $4.8B $4.5B $2.5B Avg. Annual Sales Revenue (over years 0-30) $4.3B $3.2B $2.6B $1.4B Cumulative Sales Revenue over 30 year period $134.4B $98.4B $81.7B $43.8B 6 5 4 3 2 1 0 0 5 10 15 20 25 30 Years since FDA/EMEA regulatory approval
  • 7.
  • 8.
  • 9.
  • 10. COMPLETE PLANNED Product Portfolio O11_IRG / NOT REQUIRED
  • 12.
  • 13. Phase 1 Human Trial – Government Supported Published by The Journal of Infectious Diseases Challenge Dose 30-300 Times Higher Than Typical Human Dose DNA Vaccine with GM-CSF Adjuvant (Primate Data) O11_IRG / 0 80 100 60 40 20 Number of Challenges 0 2 4 6 8 12 10 Percent Uninfected 70% Prevention of Infection 5 / 7 No Evidence of Infection – To Date >12 Months 100% Infection Controls (0 / 15 Protected)
  • 15.
  • 16. Unpublished Data: Dr. Rama Amara & Dr. Harriet Robinson 100x 1000x VACCINATION Pre-Clinical Therapeutic Trial Results O11_IRG / RJu9 Rlr9   0 12 50 58 66 72 112 10 7 10 5 10 3 Weeks Following Infection Infection Drug Treatment Started DNA DNA MVA Drug Treatment Interruption
  • 18.
  • 19. Rate of Vaccine Responses * Responding T cells, intracellular cytokine staining ** Anti-Env binding AB, ELISA *** After 6 intrarectal challenges with a dose 40-400 times higher than typical human dose NOTE: Polio Vaccine is 60-70% effective / Flu Vaccine 70-90% effective O11_XTRA /
  • 20. Current Status: Therapeutic AIDS Vaccines O11_XTRA / Vaccine Sponsor Antibody (Ab to Env) T Cell Comments Bavarian Nordic MVA/BN Multiantigen NO YES Phase 1 Completed CD4 & CD8 T cells Bionor Immuno Vacc-4x Peptides NO YES Phase 2 Completed CD4 T cells but limited Response Rates Inovio PENNVAX™-B (pDNA) Unknown YES Phase 1 Active U Penn vaccine, CD4 & CD8 T cells Profectus BioSciences Multiantigen DNA + rVSV Unknown Unknown 2010 Start Planned ACTG Study GSK gp120+nef/tat fusion proteins & adjuvant YES YES Phase 1 Completed Low level neutralizing Ab, CD4 T cells Argos Therapeutics AGS-004 (RNA transfect DC) NO YES Phase 2b Active Personalized medicine approach GEOVAX DNA / MVA YES * YES * Phase 1 Enrolling * Data from GV Phase 1 trial in HIV Uninfected
  • 21. Current Status: Preventative AIDS Vaccines Out of more than 80 vaccines entering HVTN Phase 1 testing, GeoVax Vaccines represent 2 of 6 to progress to Phase 2 O11_XTRA / Vaccine Sponsor Antibody (Ab to Env) T Cell Comments VaxGen gp 120 YES NO FAILED gp120, atypical Env Merck Ad5 NO YES FAILED Ad5 seropositive participants at higher risk NIH / VRC DNA Ad5 YES YES ENROLLING Limited to Ad5 seronegative, circumcised Not intended as commercial product Aventis ALVAC / gp120 YES LOW TRIAL COMPLETE Prevention of infection in 31% of Participants GEOVAX DNA / MVA YES YES PHASE 2a Enrollment Complete GEOVAX MVA / MVA YES YES PHASE 2a Addendum Enrollment Started December 2010
  • 22.
  • 23. GeoVax Labs, Inc. Thank You!!